Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2023 Jan 9;13:1123234. doi: 10.3389/fphar.2022.1123234

Erratum: Advances in RIPK1 kinase inhibitors

Frontiers Production Office1,*
PMCID: PMC9868424  PMID: 36699094

Due to a production error, the list of affiliations used for the authors was incorrect. The correct affiliations list is shown below.

Lu Chen1,2,†, Xiaoqin Zhang3,†, Yaqing Ou4,†, Maoyu Liu1,2,†, Dongke Yu1,2, Zhiheng Song5, Lihong Niu6,*, Lijuan Zhang1,2,* and Jianyou Shi1,2,*

1Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

2Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

3Department of Critical Care Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China

4Department of Pharmacy, The Affiliated Chengdu 363 Hospital of Southwest Medical University, Chengdu, Sichuan, China

5Suzhou University of Science and Technology, Suzhou, Jiangsu, China, 6 Institute of Laboratory Animal Sciences, Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China

The publisher apologizes for this mistake. The original version of this article has been updated.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES